RxSight’s (RXST) Sell (E+) Rating Reaffirmed at Weiss Ratings
Weiss Ratings has once again assigned RxSight a “sell (E+)” rating. Another research analyst, Wall Street Zen, similarly adjusted its stance from “hold” to “sell,” indicating a continued sense of caution around RxSight’s stock.
1 day ago
1 min read
